Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
7.84
+0.04 (0.51%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cogent Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | - | - | - | - | 7.87 | 22.5 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -65.02% | 169.13% | Upgrade
|
| Cost of Revenue | - | - | - | - | 25.74 | 43.71 | Upgrade
|
| Gross Profit | - | - | - | - | -17.87 | -21.21 | Upgrade
|
| Selling, General & Admin | 41.1 | 34.38 | 26.21 | 19.64 | 17.42 | 10.97 | Upgrade
|
| Research & Development | 219.33 | 173.76 | 121.63 | 55.91 | - | - | Upgrade
|
| Operating Expenses | 260.43 | 208.13 | 147.84 | 75.55 | 17.42 | 10.97 | Upgrade
|
| Operating Income | -260.43 | -208.13 | -147.84 | -75.55 | -35.29 | -32.18 | Upgrade
|
| Interest & Investment Income | 18.1 | 13.08 | 3.99 | 0.47 | 0.14 | 0.27 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.11 | 2.64 | 3.21 | 2.81 | -0.25 | - | Upgrade
|
| EBT Excluding Unusual Items | -246.44 | -192.41 | -140.64 | -72.27 | -35.39 | -31.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 7.49 | 0.08 | Upgrade
|
| Asset Writedown | - | - | 0.4 | - | - | - | Upgrade
|
| Pretax Income | -242.3 | -192.41 | -140.24 | -72.27 | -74.81 | -31.83 | Upgrade
|
| Earnings From Continuing Operations | - | -192.41 | -140.24 | -72.27 | -74.81 | -31.83 | Upgrade
|
| Net Income | -242.3 | -192.41 | -140.24 | -72.27 | -74.81 | -31.83 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 104.4 | - | Upgrade
|
| Net Income to Common | -242.3 | -192.41 | -140.24 | -72.27 | -179.21 | -31.83 | Upgrade
|
| Shares Outstanding (Basic) | 98 | 80 | 59 | 39 | 11 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 98 | 80 | 59 | 39 | 11 | 8 | Upgrade
|
| Shares Change (YoY) | 29.32% | 35.61% | 51.66% | 249.52% | 45.42% | - | Upgrade
|
| EPS (Basic) | -2.48 | -2.42 | -2.39 | -1.87 | -16.17 | -4.18 | Upgrade
|
| EPS (Diluted) | -2.48 | -2.42 | -2.39 | -1.87 | -16.17 | -4.18 | Upgrade
|
| Free Cash Flow | -192.1 | -156.42 | -125.5 | -60.48 | -35.85 | -41.55 | Upgrade
|
| Free Cash Flow Per Share | -1.96 | -1.96 | -2.14 | -1.56 | -3.24 | -5.45 | Upgrade
|
| Gross Margin | - | - | - | - | -227.00% | -94.27% | Upgrade
|
| Operating Margin | - | - | - | - | -448.34% | -143.02% | Upgrade
|
| Profit Margin | - | - | - | - | -2276.81% | -141.49% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -455.47% | -184.66% | Upgrade
|
| EBITDA | -258.01 | -205.86 | -147 | -75.4 | -34.57 | -30.89 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -137.27% | Upgrade
|
| D&A For EBITDA | 2.42 | 2.27 | 0.84 | 0.15 | 0.72 | 1.29 | Upgrade
|
| EBIT | -260.43 | -208.13 | -147.84 | -75.55 | -35.29 | -32.18 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -143.02% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.